Litcius/Paper detail

Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Tilmann Graf, Thomas Thiele, Randolf Klingebiel, Andreas Greinacher, Wolf‐Rüdiger Schäbitz, Isabell Greeve

2021Journal of Neurology44 citationsDOIOpen Access PDF

Abstract

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. <em>Journal of Neurology</em>. 2021;268(12):4483-4485.

Topics & Concepts

MedicineNeurologyAbdominal painNeuroradiologyThrombosisCerebral venous sinus thrombosisAnesthesiaInternal medicinePsychiatryHeparin-Induced Thrombocytopenia and ThrombosisPlatelet Disorders and TreatmentsIntramuscular injections and effects
Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis | Litcius